New study tracks heart Drug's safety in pregnancy
NCT ID NCT05939700
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study monitors the safety of the heart medication mavacamten when taken during pregnancy or while breastfeeding. Researchers will track outcomes for mothers, fetuses, and infants up to one year after birth. The goal is to better understand any risks, not to test a new treatment. About 20 participants who have taken mavacamten during pregnancy or breastfeeding will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREASTFEEDING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
The Mavacamten Pregnancy Surveillance Program, PPD Inc
RECRUITINGWilmington, North Carolina, 28401-3331, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.